Cellebrite Beats Targets With 20% ARR Growth, Raises Full-Year EBITDA Outlook
CLBT sits 36% above its 52-week low of $9.58.
Summary
Cellebrite delivered a clean beat-and-raise quarter: ARR hit $528.5 million, up 20% year-over-year, revenue rose 18% to $149.0 million, and adjusted EBITDA came in at $53.6 million for a 36.0% margin — all above the company's own targets. Earnings per share were 10 cents, or 17 cents on an adjusted basis. Management raised full-year 2026 adjusted EBITDA guidance to $163 million to $166 million while reaffirming the ARR outlook of $550 million to $560 million and setting revenue at $553 million to $558 million, and it sees fourth-quarter revenue of $145 million to $150 million. Free cash flow was $51.8 million in the quarter, with trailing-twelve-month FCF margin at 30.9%. The one overhang is Corellium: the acquisition is still under CFIUS review and Cellebrite says it is seeking to address the committee's concerns in lieu of a potential divestment, with no final decision received. The conference call is at 8:30 a.m. ET today.
At the time of this announcement, CLBT was trading at $13.03 on NASDAQ in the Technology sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $9.58 to $19.98. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.